The promise of wide adoption of droplet microfluidics as an enabling tool for many applications has not yet been realized. The Dolomite Bio division of Blacktrace Holdings Ltd is one of the few industrial companies that has successfully translated droplet microfluidic innovations into enabling tools for high throughput experimentation used in single-cell genomics. This chapter aims to discuss the contributing factors that slow down the adoption of droplet microfluidics as an enabling tool and its future directions. It is compiled based on an interview with Mark Gilligan, CEO of Blacktrace.